0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biocept
Its shares trade under the ticker BIOCQ. It has been listed since 5 February 2014. In the fiscal year to 31 December 2022, it reported revenue of $25.9m and a net loss of $32.1m. At that date it held total assets of $30.9m and shareholders' equity of $8.9m.
Biocept, Inc. is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company is headquartered in San Diego, California. The company went IPO on 2014-02-05. The firm focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name CNSide. CNSide encompasses a suite of cellular and molecular technologies intended to aid medical professionals in CSF analysis and central nervous system (CNS) disease management in patients with solid tumors. The company offers and conducts its commercialized diagnostic assays, which include cell capture and enumeration, immunocytochemistry, fluorescent in situ hybridization (FISH), and next generation sequencing (NGS). The company has commercialized its CNSide assays for detecting and characterizing many different carcinomas and melanoma. These assays utilize its dual cellular and ctDNA technology platforms and provide biomarker analysis from a patient’s CSF sample.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 5 Feb 2014
- Employees
- 50
- Website
- biocept.com ↗
Leadership
Pay as last reported
- Mr. Bruce GerhardtIndependent Chairman of the Board$67,710
- Dr. Philippe MarchandChief Operating Officer
- Mr. Robert WalshPrincipal Accounting Officer, Vice President, Controller
- Mr. Darrell TaylorChief Legal Officer and Chief Compliance Officer$773,278
- Dr. Nathaniel SweedMedical Director
- Ms. M. Faye WilsonLead Independent Director$119,011
- Ms. Marsha ChandlerIndependent Director$70,210
- Ms. Jody CainInvestor Relations, since 2021
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biocept focuses on oncology laboratory services with 50 employees in San Diego.
- CNSide is a branded suite for CSF analysis and CNS disease management.
- Biocept commercializes diagnostic assays including cell capture and NGS technologies.
Weaknesses
- Biocept has only 50 employees and limited commercialization in the US market.
- The company's IPO was in 2014, indicating a relatively young market presence.
- Biocept's product line is limited to oncology diagnostics without broader applications.
Opportunities
- Biocept can expand its CNSide assays to more cancer types and markets.
- The growing demand for liquid biopsies in oncology presents new opportunities.
- Biocept may partner with larger healthcare providers for wider adoption.
Threats
- Biocept faces competition from established biotechnology firms in the US market.
- Regulatory changes in the Health Care sector could impact diagnostic services.
- The company's small size may limit its ability to compete with larger firms.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.